These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 24456909

  • 1. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
    Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A.
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):859-69. PubMed ID: 24456909
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep--A randomized, placebo-controlled trial.
    Kasper S, Anghelescu I, Dienel A.
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1960-7. PubMed ID: 26293583
    [Abstract] [Full Text] [Related]

  • 3. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.
    Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Dienel A, Schläfke S.
    Int Clin Psychopharmacol; 2010 Sep; 25(5):277-87. PubMed ID: 20512042
    [Abstract] [Full Text] [Related]

  • 4. Silexan does not cause withdrawal symptoms even when abruptly discontinued.
    Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A, Kasper S.
    Int J Psychiatry Clin Pract; 2017 Sep; 21(3):177-180. PubMed ID: 28319423
    [Abstract] [Full Text] [Related]

  • 5. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.
    Woelk H, Schläfke S.
    Phytomedicine; 2010 Feb; 17(2):94-9. PubMed ID: 19962288
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial.
    Kasper S, Volz HP, Dienel A, Schläfke S.
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):331-340. PubMed ID: 26718792
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis.
    Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM.
    Sci Rep; 2019 Dec 02; 9(1):18042. PubMed ID: 31792285
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.
    Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Dienel A, Schläfke S.
    Wien Med Wochenschr; 2010 Dec 02; 160(21-22):547-56. PubMed ID: 21170695
    [Abstract] [Full Text] [Related]

  • 9. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review.
    Kasper S.
    Int J Psychiatry Clin Pract; 2013 Nov 02; 17 Suppl 1():15-22. PubMed ID: 23808618
    [Abstract] [Full Text] [Related]

  • 10. Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set.
    Kasper S, Möller HJ, Volz HP, Schläfke S, Dienel A.
    Int Clin Psychopharmacol; 2017 Jul 02; 32(4):195-204. PubMed ID: 28379882
    [Abstract] [Full Text] [Related]

  • 11. Silexan in anxiety disorders: Clinical data and pharmacological background.
    Kasper S, Müller WE, Volz HP, Möller HJ, Koch E, Dienel A.
    World J Biol Psychiatry; 2018 Sep 02; 19(6):412-420. PubMed ID: 28511598
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials.
    Dold M, Bartova L, Volz HP, Seifritz E, Möller HJ, Schläfke S, Kasper S.
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct 02; 273(7):1615-1628. PubMed ID: 36717399
    [Abstract] [Full Text] [Related]

  • 13. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
    Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H.
    Int J Neuropsychopharmacol; 2010 Apr 02; 13(3):305-20. PubMed ID: 19691907
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.
    Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S.
    Eur Arch Psychiatry Clin Neurosci; 2019 Mar 02; 269(2):183-193. PubMed ID: 29150713
    [Abstract] [Full Text] [Related]

  • 15. Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials.
    Dold M, Möller HJ, Volz HP, Seifritz E, Schläfke S, Bartova L, Kasper S.
    Eur Psychiatry; 2024 Mar 01; 67(1):e23. PubMed ID: 38425206
    [Abstract] [Full Text] [Related]

  • 16. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov 01; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 17. Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect.
    Seifritz E, Schläfke S, Holsboer-Trachsler E.
    J Psychiatr Res; 2019 Aug 01; 115():69-74. PubMed ID: 31121394
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008 Aug 01; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.
    Bartova L, Dold M, Volz HP, Seifritz E, Möller HJ, Kasper S.
    Eur Arch Psychiatry Clin Neurosci; 2023 Feb 01; 273(1):51-63. PubMed ID: 35262795
    [Abstract] [Full Text] [Related]

  • 20. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 01; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.